INTRODUCTION
============

*Acinetobacter baumannii* has emerged as an important nosocomial pathogen that causes infections mainly in patients in intensive care units \[[@B1][@B2]\]. These bacteria cause various accompanying illnesses such as pneumonia, urinary tract infections, septicemia, meningitis, and wound infections in immunocompromised patients \[[@B1]\]. During the past decade, the management of *A. baumannii* infections has been a great challenge owing to the increasing number of isolates exhibiting multiple antimicrobial resistance. Multidrug-resistant *A. baumannii* (MDR-AB) infections are associated with high mortality rates and longer hospital stays \[[@B3]\]. Because optimal treatment regimens for MDR-AB isolates are not well defined, the discovery of new treatments, including combination therapy, is required.

Carbapenems have been commonly used as the treatment of choice for MDR-AB infections \[[@B4]\]. However, MDR-AB isolates resistant to carbapenems have been increasingly reported worldwide \[[@B5][@B6][@B7]\]. Recently, colistin and tigecycline have emerged as alternative therapeutic options for MDR-AB infections \[[@B8][@B9][@B10][@B11]\]. However, resistance to these antimicrobial agents has also been reported as a result of the increased usage of colistin and tigecycline \[[@B8][@B12][@B13][@B14]\]. Thus, many recent studies have investigated combinations of two or more agents for treating MDR-AB infections. Specifically, studies on combinations including colistin have frequently been reported \[[@B13]\]. Colistin combination treatment is useful for preventing antibiotic resistance and reducing toxicity \[[@B15]\]. Doripenem, the latest broad-spectrum carbapenem approved in the United States, is more stable against carbapenemase than other carbapenems \[[@B16]\]. Thus, doripenem has emerged as a new treatment option for MDR-AB infections.

Thus far, several combinations, including colistin-tigecycline and colistin-doripenem, have been reported to be effective *in vivo* or *in vitro* against MDR-AB \[[@B16][@B17]\]. However, reports on the effects of these combinations against extensively drug-resistant (XDR) and MDR-AB clinical isolates have been rarely found. In this study, we evaluated the synergistic effects of combinations of antimicrobial agents against XDR and MDR-AB isolates by *in vitro* time-kill analysis.

METHODS
=======

1. Bacterial isolates
---------------------

Of 69 *A. baumannii* clinical isolates, 64 were obtained from Chosun University during the period from January 2009 to June 2014. Five isolates, characterized in a previous study of antimicrobial resistance carried out by the Korean Antimicrobial Resistance Monitoring System (KARMS) in 2013 \[[@B18]\], were added. *A. baumannii* was initially identified by using the Vitek 2 system (bioMérieux, Marcy-l\'\'Etoile, France). Thereafter, species identification was confirmed by *gyrB* multiplex PCR. Some isolates of *A. baumannii*, identified previously upto the species level by molecular methods using *rpoB* gene sequencing and 16S rRNA gene sequencing, were also included \[[@B19]\]. Additionally, they were divided into the XDR (41 isolates) and MDR groups (28 isolates) according to the antimicrobial susceptibility patterns in the following antimicrobial categories: aminoglycosides, antipseudomonal carbapenems, antipseudomonal fluoroquinolones,antipseudomonal penicillins plus β-lactamase inhibitors, extended-spectrum cephalosporins, folate pathway inhibitors, penicillins plus β-lactamase inhibitors, polymyxins, and tetracyclines \[[@B20]\]. XDR was defined as acquired non-susceptibility to at least one agent in all but two or fewer antimicrobial categories. MDR was defined as non-susceptible to at least one agent in three or more antimicrobial categories.

2. Antibiotics and susceptibility testing
-----------------------------------------

Minimum inhibitory concentration (MIC) determinations for colistin, doripenem, and tigecycline were performed by agar dilution in accordance with the CLSI recommendations \[[@B21]\]. The antimicrobial agents used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA). Colistin and doripenem MIC results were interpreted according to the CLSI breakpoint criteria \[[@B21]\]. No breakpoints for tigecycline are available from the CLSI guidelines. Thus, the criteria of the United States Food and Drug Administration for Enterobacteriaceae were used for tigecycline (susceptibility, ≤2 µg/mL; resistance, ≥8 µg/mL) \[[@B21]\]. *Staphylococcus aureus* (ATCC 29213) and *Pseudomonas aeruginosa* (ATCC 27853) were used as quality control isolates.

3. Multilocus sequence typing (MLST) and detection of the OXA carbapenemase gene
--------------------------------------------------------------------------------

To assess interrelationship between MLST type and time-kill assay results, 35 isolates were randomly selected from 69 serially arranged isolates according to the isolation time. In the same isolates, genes encoding carbapenemases were detected by PCR and sequencing as described previously \[[@B23]\]. Nucleotide sequences obtained by PCR sequencing were compared with sequence databases using BLAST (<http://blast.ncbi.nlm.nih.gov/>). MLST was performed by PCR and sequencing analysis of seven housekeeping genes (*gltA*, *gyrB*, *gdhB*, *recA*, *cpn60*, *gpi*, *rpoD*), as described previously \[[@B23]\]. Nucleotide sequences obtained by PCR sequencing were compared with sequences pre-existing in the MLST databases (<http://pubmlst.org/abaumannii>) to assign the allelic number and sequence types (STs).

4. Time-kill assay
------------------

Time-kill assays were performed for the three antibiotics (colistine, doripenem, and tigecycline) and three antibiotic combinations (colistin-doripenem, doripenem-tigecycline, and colistin-tigecycline). Concentrations representative of clinically achievable levels (colistin: 2 µg/mL; doripenem: 8 µg/mL) \[[@B25]\] and achievable tissue levels (tigecycline: 2 µg/mL) \[[@B26]\] for each antibiotic were used in this study. Tubes containing Mueller-Hinton broth supplemented with the drug were inoculated with the test organism to a density of approximately 5×10^5^ colony-forming unit (CFU)/mL in a final volume of 10 mL and incubated in a shaker incubator at 37℃. Diluted samples (100 µL) were plated on Mueller-Hinton agar plates, and the total colony count was determined after a 24 hr incubation period at 37℃. Bactericidal activity was defined as ≥3 log~10~ CFU/mL reduction compared with the initial inoculums \[[@B17]\]. Synergism was defined as ≥2 log~10~ CFU/mL reduction with the combination compared with the most active single agent and ≥2 log~10~ CFU/mL reduction below the initial inoculum at 24 hr. Antagonism was defined as ≥2 log~10~ CFU/mL increase with the combination compared with the most active single agent at 24 hr. Indifference was defined as \<2 log~10~ change in CFU/mL at 24 hr with the combination compared with the most active single agent \[[@B27]\].

5. Statistical analysis
-----------------------

To determine whether the differences among the time-kill assay results of the three antibiotic combinations in each group were statistically significant, McNemar\'s test was conducted. Chi-square (χ^2^) test was performed to compare the differences in the results of the XDR and MDR groups for each drug combination. The SPSS 18.0 program (SPSS Inc., Chicago, IL, USA) was used, and a *P* value less than 0.05 was considered statistically significant.

RESULTS
=======

1. Antibiotic susceptibility
----------------------------

Among the 41 XDR isolates, 51.2%, 7.3%, and 29.3% of the isolates were susceptible to colistin, doripenem, and tigecycline, respectively. Among the 28 MDR isolates, 100%, 0%, and 25% of the isolates were susceptible to colistin, doripenem and tigecycline, respectively. The MIC~50~ and MIC~90~ values and percent antimicrobial resistance are presented in [Table 1](#T1){ref-type="table"}.

2. The OXA carbapenemase gene and MLST
--------------------------------------

Thirty-four (97.1%) of the 35 isolates tested for the OXA gene carried the OXA-23 gene, whereas only two (5.7%) isolates carried the IS*Aba*-OXA-51 gene. The STs identified by MLST were divided into six groups, of which the frequencies were as follows: ST191 (45.7%), ST208 (22.9%), ST737 (20%), ST357 (5.7%), ST229 (2.9%), and ST369 (2.9%).

3. Time-kill assay results
--------------------------

The time-kill assay results for all *A. baumannii* isolates are presented in [Table 2](#T2){ref-type="table"}. Colistin-doripenem showed the highest synergy rate in both the XDR (53.7%) and MDR (53.6%) groups. By contrast, doripenem-tigecycline showed the lowest synergy rate in both the XDR (14.6%) and MDR (14.3%) groups. The difference in the time-kill assay results between the XDR and MDR groups with regard to all antibiotic combinations are shown in [Table 3](#T3){ref-type="table"}. The significant difference of the time-kill assay results was found between following antibiotic combinations: colistin-doripenem vs. doripenem-tigecycline (*P*=0.000); colistin-tigecycline vs. doripenem-tigecycline (*P*=0.000) in the XDR group and colistin-doripenem vs. doripenem-tigecycline (*P*=0.003) in the MDR group ([Table 3](#T3){ref-type="table"}). However, no significant difference was found between the time-kill assay results of the XDR and MDR group for each drug combination. Antagonism was observed for doripenem-tigecycline and colistin-tigecycline combinations. Among the total number of isolates, doripenem-tigecycline showed a relatively high percentage (5.8%) of antagonism compared with that of colistin-tigecycline (1.4%).

The rate of bactericidal activity increased from 23.2% for the most active single agent to 75.4% for the colistin-doripenem combination among the total number ofisolates. The rate of bactericidal activity increased from 11.6% for the best single agent to 24.6% for the doripenem-tigecycline combination. The rate of bactericidal activity rose from 23.2% for the single most active agent to 63.8% for the colistin-tigecycline combination.

DISCUSSION
==========

Several *in vitro* studies have reported synergy rates against *A. baumannii* for the colistin-doripenem, colistin-tigecycline, and doripenem-tigecycline combinations as 33.3-100%, 8.3-100%, and 33.3%, respectively \[[@B15][@B17][@B22][@B28][@B29][@B30]\].

In our study, antibiotic combinations were found to be superior to monotherapy, with regard to bactericidal activity in the XDR and MDR groups. In previous studies, the colistin-doripenem combination was reported to have a better therapeutic effect than the colistin-tigecycline combination against XDR-AB infection \[[@B31][@B32]\]. However, no significant difference between the two combinations was found in our study. In agreement with the previous results \[[@B33]\], the synergy rate of the doripenem-tigecycline combination was found to be low (14.6%) in the present study. Several *in vitro* studies of XDR-AB isolates have shown higher synergy rates (72-100%) for the colistin-doripenem and colistin-tigecycline combinations compared with our results (43.9-53.7%) \[[@B25][@B34][@B35]\].

Although the exact causes for the different synergy rates between various studies are unknown, they may be attributable to differences in sample size, regional epidemiologic features, test methods used, and interpretation criteria for the synergy. A previous study revealed that synergy rates vary according to the test method used (time-kill assay, E test, chequerboard test) \[[@B36]\]. In addition, the synergy rate differed between studies because each used different interpretation criteria for synergy. For example, Principe et al. \[[@B17]\] admitted synergistic activity at any time the criteria for synergy were fulfilled, whereas the present study admitted synergy at 24 hr post-inoculation. Applying the criteria for synergy in the present study converted all four synergy cases discussed by Principe et al. \[[@B17]\] into indifference cases because synergy was not found at 24 hr. Appropriate comparison of the synergy rates in different studies requires the establishment of a standard protocol, including common interpretation criteria.

Dinc et al. \[[@B16]\] reported that the doripenem-tigecycline combination was more effective than the colistin-doripenem combination in their *in vivo* study. In contrast, doripenem-tigecycline showed the lowest synergy rate in the MDR groups in our study. It is known that *in vitro* study results are not always similar to those of *in vivo* studies, because *in vivo* environments cannot be completely mimicked *in vitro* \[[@B36]\]. Therefore, the results obtained from *in vitro* studies need to be supported by further *in vivo* studies before these results are used to inform clinical practice.

In the present study, antagonism was detected for doripenem-tigecycline and colistin-tigecycline combinations in the total number of isolates, and antagonistic rates varied from 0% to 10.7% ([Table 3](#T3){ref-type="table"}). In particular, the doripenem-tigecycline combination showed the highest antagonistic activity in the MDR group. In contrast, antagonism was not detected against *A. baumanii* isolates with the colistin, doripenem, and tigecycline combinations in most previous studies \[[@B15][@B17][@B22][@B25][@B29][@B34][@B35]\]. Thus far, the tigecycline-piperacillin/tazobactam, tigecycline-amikacin, and colistin-tigecycline combinations have shown antagonistic activity \[[@B30]\]. However, the underlying cause of the antagonism demonstrated in the use of combinations of antibiotics against *A. baumannii* isolates has not been clearly identified.

Such dissimilar or even discrepant results have also been reported in the field of drug interaction \[[@B37][@B38]\]. Although the reasons for such differences are not clear, some contributing factors or possible causes have been postulated. For example, the concentration of drug components used and the ratio in which the two drug components co-exist may affect the results of drug interaction. Other possible contributing or influential factors for the differing interactions include differences in species, strain, the time required for whole test procedure, the read-outs for growth in culture, infection, dosing regimens, and efficacy criteria in animal models used in each study \[[@B37]\]. Although we could not fully explain the reasons for these differences in the rates of synergism or antagonism in the present study and most time-kill assay studies, we suspect differences in the concentrations of drugs used to be the main cause of the different results. Most studies for drug interaction have tested diverse concentrations of drugs ranging from 1/4×MIC to 4×MIC of each isolates, usually using small number of bacterial isolates. We have tested a single achievable serum concentration for each drug using larger number of isolates. Taken as a whole, these findings underscore the importance of standardization of isolates, methods, and analysis to identify the worthiest combinations of drugs recognized previously \[[@B37]\]. Further studies such as comparison studies of diverse methods implementing standardized protocols may help to explain such differences in the future.

The frequencies of synergy were similar among different ST clusters of *A. baumannii* in this study (data not shown). Because the results of the time-kill assay of isolates belonging to the same ST clusters vary from isolate to isolate, it may be necessary to perform the synergy test individually for each isolate.

In summary, the colistin-doripenem combination showed the highest rate of synergy and bactericidal activity and no antagonistic reaction in XDR- and MDR-AB. Since the effects of colistin-tigecycline and doripenem-tigecycline combinations were not only synergistic but also antagonistic, it is important to check possible interactions between candidate drugs before adopting combination therapy. The present data may provide useful information for clinicians while considering optimal treatment options for MDR-AB infections.

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant number:NRF-2011-0025617). This study was supported by research fund from Chosun University, 2015.

**Authors\' Disclosures of Potential Conflicts of Interest:** No potential conflicts of interest relevant to this article were reported.

###### MIC results of colistin, doripenem, and tigecycline for 41 XDR and 28 MDR clinical isolates of *A. baumannii*

![](alm-36-124-i001)

  Antibiotics   MIC Result (µg/mL)   Susceptibility (%)             
  ------------- -------------------- -------------------- --------- ------
  Colistin                                                          
   XDR          2                    8                    1-16      51.2
   MDR          0.5                  1                    0.25-2    100
   Total        1                    8                    0.25-16   71
  Doripenem                                                         
   XDR          64                   256                  1-\>256   7.3
   MDR          32                   64                   8-\>256   0
   Total        32                   128                  1-\>256   4.3
  Tigecycline                                                       
   XDR          8                    64                   0.5-64    29.3
   MDR          4                    32                   0.5-64    25
   Total        32                   64                   0.5-64    27.5

Abbreviations: MIC, minimum inhibitory concentration; XDR, extensively drug-resistant; MDR, multidrug-resistant.

###### Results of time-kill assay and bactericidal activity against two-drug combinations of colistin, doripenem, and tigecycline of 41 XDR and 28 MDR clinical isolates of *A. baumannii*
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  Isolate   MIC (µg/mL)   Time-kill assay results   Bactericidal activity         Isolate   MIC (µg/mL)   Time-kill assay results   Bactericidal activity                                                                
  --------- ------------- ------------------------- ----------------------- ----- --------- ------------- ------------------------- ----------------------- --- --- ----- ------ ------- ----- ----- ----- ----- --- --- ---
  XDR                     36                        0.5                     64    32        I             I                         I                       B   N   N                                                    
  1         1             2                         32                      Syn   I         I             B                         N                       N       37    1      32      1     I     Syn   Syn   N   B   B
  2         1             2                         64                      Syn   I         Syn           B                         N                       B       38    1      1       64    Syn   I     I     N   B   B
  3         0.5           64                        2                       I     I         I             B                         B                       B       39    8      8       1     I     I     Syn   B   B   B
  4         0.5           32                        1                       I     I         I             N                         N                       N       40    8      8       0.5   I     I     I     B   N   B
  5         0.5           64                        16                      I     I         I             N                         N                       N       41    8      \>256   1     Syn   I     I     B   N   N
  6         16            32                        4                       Syn   Syn       Syn           B                         B                       B       MDR                                                  
  7         8             \>256                     32                      I     I         I             N                         B                       B       1     0.25   64      0.5   Syn   I     Syn   B   N   B
  8         8             32                        2                       I     I         I             N                         N                       N       2     0.5    16      4     Syn   Syn   I     B   B   N
  9         16            32                        8                       I     I         An            N                         N                       N       3     2      32      4     I     Syn   I     N   N   N
  10        8             256                       2                       Syn   Syn       Syn           B                         N                       B       4     0.25   \>256   2     I     I     I     N   N   N
  11        0.5           64                        4                       Syn   I         Syn           B                         N                       B       5     0.25   32      4     Syn   I     Syn   B   N   N
  12        2             128                       32                      I     I         I             B                         B                       B       6     0.25   32      4     Syn   I     I     B   B   B
  13        2             32                        64                      Syn   I         I             B                         N                       N       7     0.25   32      4     Syn   I     I     B   B   B
  14        1             64                        4                       Syn   Syn       Syn           B                         B                       B       8     0.5    64      64    Syn   I     Syn   N   N   B
  15        1             128                       4                       I     I         I             B                         N                       B       9     1      64      4     I     I     I     B   N   B
  16        2             32                        2                       I     I         Syn           N                         N                       N       10    0.5    32      4     Syn   I     Syn   B   N   B
  17        8             64                        8                       Syn   I         Syn           B                         N                       B       11    0.5    32      4     Syn   An    I     B   N   B
  18        0.5           64                        64                      I     I         I             N                         N                       N       12    0.5    32      4     I     I     I     B   N   N
  19        1             64                        64                      Syn   I         I             B                         N                       N       13    0.5    32      4     I     I     I     N   N   N
  20        8             8                         2                       Syn   Syn       Syn           B                         B                       B       14    0.5    16      1     Syn   I     I     B   N   N
  21        0.25          32                        8                       Syn   I         Syn           B                         N                       B       15    0.25   64      2     Syn   Syn   I     B   B   N
  22        16            32                        8                       I     I         I             N                         N                       N       16    0.5    32      4     I     I     I     B   N   N
  23        8             64                        16                      Syn   I         Syn           B                         N                       B       17    1      8       4     I     I     I     B   N   B
  24        4             128                       2                       I     I         I             B                         N                       B       18    0.5    8       1     I     I     I     B   N   B
  25        8             32                        32                      Syn   Syn       Syn           B                         B                       B       19    0.5    32      32    I     I     I     B   N   B
  26        1             64                        16                      I     I         I             N                         N                       B       20    0.5    64      4     I     I     Syn   B   B   B
  27        1             32                        4                       Syn   I         I             B                         N                       N       21    0.5    64      32    I     An    Syn   B   N   B
  28        0.5           32                        8                       Syn   An        Syn           B                         N                       B       22    0.5    32      4     I     I     Syn   B   N   B
  29        8             64                        16                      Syn   I         Syn           B                         B                       B       23    0.5    32      4     Syn   I     I     B   N   B
  30        8             32                        8                       Syn   I         Syn           B                         N                       B       24    0.5    32      4     Syn   I     Syn   B   N   B
  31        4             32                        4                       Syn   I         I             B                         N                       N       25    0.5    64      32    Syn   I     Syn   B   N   B
  32        8             64                        4                       Syn   I         I             B                         N                       N       26    0.5    64      16    Syn   I     I     B   B   B
  33        8             256                       2                       I     I         I             B                         N                       B       27    0.5    16      1     Syn   Syn   Syn   N   N   N
  34        1             64                        64                      Syn   I         Syn           B                         N                       B       28    0.5    32      2     I     An    I     B   N   B
  35        8             256                       32                      I     I         Syn           N                         N                       B                                                            

Abbreviations: MIC, minimum inhibitory concentration; CST, colistin; TGC, tigecycline; DRP, doripenem; Pos, positive; Neg, negative; Syn, synergy; I, Indifference; An, antagonism; B, bactericidal; N, non-bactericidal; XDR, extensively drug-resistant; MDR, multidrug-resistant.

###### Comparison of time-kill assay results between XDR and MDR groups^\*^ against two-drug combinations of colistin, doripenem, and tigecycline^†^
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  Combination of antibiotics   Interaction   XDR (N = 41) N (%)   MDR (N = 28) N (%)   Total (N = 69) N (%)
  ---------------------------- ------------- -------------------- -------------------- ----------------------
  CST+DRP                      Synergy       22 (53.7)            15 (53.6)            37 (53.6)
  Indifference                 19 (46.3)     13 (46.4)            32 (46.4)            
  Antagonism                   0 (0)         0 (0)                0 (0)                
  Bactericidal activity        29 (70.7)     23 (82.1)            52 (75.4)            
  DRP+TGC                      Synergy       6 (14.6)             4 (14.3)             10 (14.5)
  Indifference                 34 (82.9)     21 (75)              55 (79.7)            
  Antagonism                   1 (2.4)       3 (10.7)             4 (5.8)              
  Bactericidal activity        11 (26.8)     6 (21.4)             17 (24.6)            
  CST+TGC                      Synergy       18 (43.9)            10 (35.7)            28 (40.6)
  Indifference                 22 (53.7)     18 (64.3)            40 (58)              
  Antagonism                   1 (2.4)       0 (0)                1 (1.4)              
  Bactericidal activity        26 (64.4)     18 (64.3)            44 (63.8)            

^\*^No significant difference was found between the XDR and MDR group for each drug combination (χ^2^ test); ^†^Comparison pairs showing statistically significant differences among antibiotic combinations in time-kill results: CST-DRP vs. DRP-TGC (*P*=0.000) and CST-TGC vs. DRP-TGC (*P*=0.000) in the XDR group; CST-DRP vs. DRP-TGC (*P*=0.003) in the MDR group (McNemar\'s test).

Abbreviations: XDR, extensively drug-resistant; MDR, multidrug-resistant; CST, colistin; DRP, doripenem; TGC, tigecycline.
